Focused On-demand Library for POU domain, class 4, transcription factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q01851

UPID:

PO4F1_HUMAN

Alternative names:

Brain-specific homeobox/POU domain protein 3A; Homeobox/POU domain protein RDC-1; Oct-T1

Alternative UPACC:

Q01851; Q14986; Q15318; Q5T227

Background:

POU domain, class 4, transcription factor 1 (POU4F1), also known as Brain-specific homeobox/POU domain protein 3A, plays a pivotal role in neuronal development and function. It acts as a multifunctional transcription factor, regulating genes involved in differentiation, survival, and synaptic protein expression in neuronal lineages. Its ability to activate BCL2 expression and protect neuronal cells from apoptosis highlights its significance in neuroprotection.

Therapeutic significance:

Given its involvement in Ataxia, intention tremor, and hypotonia syndrome, childhood-onset, understanding the role of POU4F1 could open doors to potential therapeutic strategies. Its regulatory effect on gene expression and neuronal survival positions it as a key target for addressing neurodevelopmental disorders.